IN2014MN01892A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN01892A IN2014MN01892A IN1892MUN2014A IN2014MN01892A IN 2014MN01892 A IN2014MN01892 A IN 2014MN01892A IN 1892MUN2014 A IN1892MUN2014 A IN 1892MUN2014A IN 2014MN01892 A IN2014MN01892 A IN 2014MN01892A
- Authority
- IN
- India
- Prior art keywords
- dihydroquinazolin
- cyclodextrins
- piperazin
- methoxyphenyl
- arginine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to pharmaceutical preparations in particular for intravenous administration which contain {8 fluoro 2 [4 (3 methoxyphenyl)piperazin 1 yl] 3 [2 methoxy 5 (trifluoromethyl)phenyl] 3 4 dihydroquinazolin 4 yl} acetic acid in combination with at least one auxiliary agent selected from the cyclodextrins lysine and arginine to methods for the production thereof and to the use thereof to treat and/or prevent diseases in particular the use thereof as antiviral agents preferably against cytomegaloviruses.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102012101680A DE102012101680A1 (en) | 2012-02-29 | 2012-02-29 | Pharmaceutical preparation containing an antiviral dihydroquinazoline derivative |
| PCT/EP2013/054114 WO2013127970A1 (en) | 2012-02-29 | 2013-02-28 | Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01892A true IN2014MN01892A (en) | 2015-07-10 |
Family
ID=47757622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1892MUN2014 IN2014MN01892A (en) | 2012-02-29 | 2013-02-28 |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US10603384B2 (en) |
| EP (3) | EP4328218A3 (en) |
| JP (1) | JP6387486B2 (en) |
| KR (1) | KR102149561B1 (en) |
| CN (2) | CN110433166A (en) |
| AU (1) | AU2013224947B2 (en) |
| BR (1) | BR112014020946B1 (en) |
| CA (1) | CA2865203C (en) |
| CL (1) | CL2014002306A1 (en) |
| CO (1) | CO7061076A2 (en) |
| CY (1) | CY1121910T1 (en) |
| DE (1) | DE102012101680A1 (en) |
| DK (2) | DK3556350T3 (en) |
| EA (1) | EA026584B1 (en) |
| ES (1) | ES2741698T3 (en) |
| FI (1) | FI3556350T3 (en) |
| HK (1) | HK1205462A1 (en) |
| HR (2) | HRP20240197T1 (en) |
| HU (1) | HUE045949T2 (en) |
| IL (1) | IL234363B (en) |
| IN (1) | IN2014MN01892A (en) |
| LT (2) | LT3556350T (en) |
| MA (1) | MA35941B1 (en) |
| ME (1) | ME03448B (en) |
| MX (1) | MX369666B (en) |
| MY (1) | MY172310A (en) |
| NZ (1) | NZ628444A (en) |
| PH (1) | PH12014501937A1 (en) |
| PL (2) | PL3556350T3 (en) |
| PT (2) | PT2819648T (en) |
| RS (2) | RS65137B1 (en) |
| SG (1) | SG11201405294XA (en) |
| SI (2) | SI2819648T1 (en) |
| TN (1) | TN2014000345A1 (en) |
| UA (1) | UA111415C2 (en) |
| WO (1) | WO2013127970A1 (en) |
| ZA (1) | ZA201405949B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11864912B2 (en) | 2016-06-03 | 2024-01-09 | Atreya Innovations Private Limited | Device for the detection and reliable capturing of the pulse characteristics |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10319612A1 (en) * | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituted dihydroquinazolines |
| DK3010891T3 (en) * | 2013-06-19 | 2019-06-24 | Aicuris Anti Infective Cures Gmbh | AMORF LETERMOVIR AND SOLID PHARMACEUTICAL FORMULATIONS FOR ORAL ADMINISTRATION |
| AU2018230991B2 (en) * | 2017-03-06 | 2023-07-13 | VenatoRx Pharmaceuticals, Inc. | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
| UY39099A (en) | 2020-02-27 | 2021-08-31 | Aic246 Gmbh & Co Kg | 2 - [(4S) -8-FLUORO-2- [4- (3-METOXIFENIL) PIPERAZIN-1-IL] -3- [2-METOXI-5- (TRIFLUOROMETIL) FENIL] -4H-QUINAZOLIN-4-IL ] SODIUM ACETATE AND PHARMACEUTICAL COMPOSITIONS THEREOF |
| UY39095A (en) | 2020-02-27 | 2021-09-30 | Aic246 Gmbh & Co Kg | PHARMACEUTICAL COMPOSITIONS INCLUDING 2- [(4S) -8-FLUORO-2- [4- (3-METOXIFENIL) PIPERAZIN-1-IL] -3- [2-METOXY-5- (TRIFLUOROMETIL) PHENYL] -4H ACETATE -QUINAZOLIN-4-IL] AND SODIUM IONS |
| CN114539085B (en) * | 2020-11-26 | 2023-10-20 | 山东诚创蓝海医药科技有限公司 | Preparation of ureido derivatives |
| CN115403528A (en) * | 2021-05-27 | 2022-11-29 | 南京正大天晴制药有限公司 | Process for preparing amorphous 3, 4-dihydroquinazoline derivatives |
| CN113880776B (en) * | 2021-11-16 | 2023-06-16 | 山东诚创蓝海医药科技有限公司 | Preparation method of rituximab intermediate |
| AR128035A1 (en) | 2021-12-21 | 2024-03-20 | Aic246 Ag & Co Kg | PHARMACEUTICAL COMPOSITIONS COMPRISING 2-[(4S)-8-FLUORO-2-[4-(3-METHOXYPHENYL)PIPERAZIN-1-IL]-3-[2-METHOXY-5-(TRIFLUOROMETHYL)PHENYL]-4H ACETATE -QUINAZOLIN-4-IL] AND POTASSIUM IONS |
| CN115322157B (en) * | 2022-06-02 | 2023-12-05 | 浙江车头制药股份有限公司 | Letermopevir intermediate compound, preparation method and application thereof |
| CN115677539B (en) * | 2022-11-01 | 2023-10-24 | 南京工业大学 | Method for high-selectivity monoalkenyl of urea group-oriented aromatic hydrocarbon under mild condition by cobalt catalysis |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1242699A (en) * | 1985-02-01 | 1988-10-04 | Bristol-Myers Company | Cefbuperazone and derivatives thereof |
| FR2585705B1 (en) * | 1985-08-05 | 1989-01-13 | Bristol Myers Co | CEPHALOSPORIN SALTS AND INJECTABLE COMPOSITIONS |
| JP3552240B2 (en) * | 1993-02-23 | 2004-08-11 | 第一製薬株式会社 | High concentration TCF preparation |
| JPH11209277A (en) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | Pharmaceutical composition |
| IT1304190B1 (en) * | 1998-12-18 | 2001-03-08 | Euphar Group Srl | DEHYDROEPIANDROSTERONE CLATRATES AND RELATED PHARMACEUTICAL COMPOSITIONS |
| SK287238B6 (en) * | 1999-03-17 | 2010-04-07 | Astrazeneca Ab | Amide derivatives, processes for preparing them, pharmaceutical composition containing these compounds, and their use |
| AU2000249111A1 (en) | 2000-05-30 | 2001-12-11 | Dr. Reddy's Research Foundation | New pharmaceutical composition and the process for its preparation |
| DE10319612A1 (en) * | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituted dihydroquinazolines |
| SI1689724T1 (en) * | 2003-11-25 | 2012-04-30 | Novartis Ag | Quinazolinone compounds as anticancer agents |
| ATE421518T1 (en) * | 2005-02-10 | 2009-02-15 | Bristol Myers Squibb Co | DIHYDROQUINAZOLINONES AS 5HT MODULATORS |
| DE102005027517A1 (en) * | 2005-06-15 | 2006-12-21 | Bayer Healthcare Ag | Process for the preparation of dihydroquinazolines |
| US8743287B2 (en) * | 2009-07-24 | 2014-06-03 | Broadcom Corporation | Method and system for mitigating motion trail artifacts and improving low contrast contours in temporal filtering based noise reduction |
-
2012
- 2012-02-29 DE DE102012101680A patent/DE102012101680A1/en not_active Ceased
-
2013
- 2013-02-28 EP EP24150976.9A patent/EP4328218A3/en active Pending
- 2013-02-28 PT PT13707000T patent/PT2819648T/en unknown
- 2013-02-28 LT LTEP19176985.0T patent/LT3556350T/en unknown
- 2013-02-28 ES ES13707000T patent/ES2741698T3/en active Active
- 2013-02-28 EA EA201400963A patent/EA026584B1/en unknown
- 2013-02-28 US US14/381,290 patent/US10603384B2/en active Active
- 2013-02-28 JP JP2014559233A patent/JP6387486B2/en active Active
- 2013-02-28 BR BR112014020946-4A patent/BR112014020946B1/en active IP Right Grant
- 2013-02-28 NZ NZ628444A patent/NZ628444A/en unknown
- 2013-02-28 MY MYPI2014002461A patent/MY172310A/en unknown
- 2013-02-28 EP EP19176985.0A patent/EP3556350B1/en active Active
- 2013-02-28 EP EP13707000.9A patent/EP2819648B1/en active Active
- 2013-02-28 MX MX2014010364A patent/MX369666B/en active IP Right Grant
- 2013-02-28 FI FIEP19176985.0T patent/FI3556350T3/en active
- 2013-02-28 CN CN201910661203.8A patent/CN110433166A/en active Pending
- 2013-02-28 RS RS20240135A patent/RS65137B1/en unknown
- 2013-02-28 PT PT191769850T patent/PT3556350T/en unknown
- 2013-02-28 CA CA2865203A patent/CA2865203C/en active Active
- 2013-02-28 DK DK19176985.0T patent/DK3556350T3/en active
- 2013-02-28 SI SI201331541T patent/SI2819648T1/en unknown
- 2013-02-28 AU AU2013224947A patent/AU2013224947B2/en active Active
- 2013-02-28 DK DK13707000.9T patent/DK2819648T3/en active
- 2013-02-28 SI SI201332077T patent/SI3556350T1/en unknown
- 2013-02-28 PL PL19176985.0T patent/PL3556350T3/en unknown
- 2013-02-28 UA UAA201410519A patent/UA111415C2/en unknown
- 2013-02-28 CN CN201380011670.7A patent/CN104144678A/en active Pending
- 2013-02-28 WO PCT/EP2013/054114 patent/WO2013127970A1/en active Application Filing
- 2013-02-28 PL PL13707000T patent/PL2819648T3/en unknown
- 2013-02-28 RS RSP20191076 patent/RS59157B1/en unknown
- 2013-02-28 IN IN1892MUN2014 patent/IN2014MN01892A/en unknown
- 2013-02-28 HU HUE13707000A patent/HUE045949T2/en unknown
- 2013-02-28 KR KR1020147023803A patent/KR102149561B1/en active IP Right Grant
- 2013-02-28 SG SG11201405294XA patent/SG11201405294XA/en unknown
- 2013-02-28 ME MEP-2019-219A patent/ME03448B/en unknown
- 2013-02-28 LT LTEP13707000.9T patent/LT2819648T/en unknown
- 2013-02-28 HR HRP20240197TT patent/HRP20240197T1/en unknown
-
2014
- 2014-08-08 TN TNP2014000345A patent/TN2014000345A1/en unknown
- 2014-08-13 ZA ZA2014/05949A patent/ZA201405949B/en unknown
- 2014-08-28 PH PH12014501937A patent/PH12014501937A1/en unknown
- 2014-08-28 CO CO14189543A patent/CO7061076A2/en unknown
- 2014-08-28 IL IL234363A patent/IL234363B/en active IP Right Grant
- 2014-08-29 CL CL2014002306A patent/CL2014002306A1/en unknown
- 2014-09-17 MA MA37360A patent/MA35941B1/en unknown
-
2015
- 2015-06-25 HK HK15106080.1A patent/HK1205462A1/en unknown
-
2019
- 2019-07-30 HR HRP20191369 patent/HRP20191369T1/en unknown
- 2019-08-20 CY CY20191100885T patent/CY1121910T1/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11864912B2 (en) | 2016-06-03 | 2024-01-09 | Atreya Innovations Private Limited | Device for the detection and reliable capturing of the pulse characteristics |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01892A (en) | ||
| PH12015501964A1 (en) | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c | |
| SG10201804552WA (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
| IN2015DN01156A (en) | ||
| PH12015501404B1 (en) | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| WO2014004993A3 (en) | Methods of reducing ldl-p | |
| MX2014002171A (en) | Combination treatments for hepatitis c. | |
| MX356728B (en) | Pharmaceutical combination for use in the treatment of diabetes type 2. | |
| GEP20186880B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| MX2015015036A (en) | Methods for improving lipid profiles using atrasentan. | |
| MY168778A (en) | Oligonucleotide chelate complex-polypeptide compositions and methods | |
| MX2013002208A (en) | Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes. | |
| GEP20156332B (en) | Pyrazoles as crth2 antagonists | |
| AU2012307449A8 (en) | Sulfonic acid salts of heterocyclylamide-substituted imidazoles | |
| WO2014104989A8 (en) | Pharmaceutical compositions comprising aripiprazole | |
| WO2012108794A3 (en) | 1,2,4-triazol-3-ylthioglycolic acid derivatives for use in therapy | |
| RS54022B1 (en) | Viral inhibitor composition for in vivo therapeutic use | |
| IN2013MU01248A (en) | ||
| IN2013MU01250A (en) | ||
| IN2013MU01249A (en) | ||
| IN2013MU01247A (en) | ||
| IN2013MU01245A (en) | ||
| IN2013MU01244A (en) | ||
| IN2013MU01246A (en) | ||
| IN2013MU01242A (en) |